Bringing the fundamentals into focus…
Back to Tarsus Pharmaceuticals, Inc.
How Tarsus Pharmaceuticals, Inc. stacks up
TARS · against 306 other Healthcare companies of similar size
Valuation
8/ 100
Near the bottom of its peers.
Ranked #232 of 307 · scores higher than 3% of peers
Bars: peers in each 10-point band of the valuation score76 peers with a valuation score of 0–9, including TARS · Click a bar to see the companies
Why valuation scores 8?
Weighted metrics compared with all Healthcare companies.Mainly because of its EBITDA yield and earnings yield, which are weaker than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. EBITDA yield: -1.6% vs peer median 4.0%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -1.4% vs peer median 1.5%
- Free cash flow yield is close to the peer norm. Free cash flow yield: 1.8% vs peer median 0.0%
Metric by metric
Position: dot = TARS, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | TARS | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 303 reported | -1.5% | 2.4% | 29% | 30% | |
| EBITDA yieldHigher is better · 301 reported | -1.6% | 4.8% | 21% | 50% | |
| Free cash flow yieldHigher is better · 158 reported | 1.6% | 0.5% | 57% | 20% | |
| Book yieldHigher is better · 301 reported | 11.0% | 28.9% | 16% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around TARS| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 37.3B HKD (≈$4.8B) | 99 | 90 | |
| 1 | 40.2B MXN (≈$2.2B) | 99 | 71 | |
| 232 | 2.0B USD | 8 | 53 | |
| 232 | 2.0B USD | 8 | 44 | |
| 232 | 5.4B USD | 8 | 24 | |
| 232 | 1.7B USD | 8 | 30 | |
| 232 | 3.4B USD | 8 | 48 | |
| 232 | 3.9B USD | 8 | 52 | |
| 232 | 2.2B USD | 8 | 23 | |
| 232 | 2.0B USD | 8 | 42 | |
| 232 | 2.2B USD | 8 | 35 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score